| 发明名称 | Use of chimeric antigen receptor-modified T-cells to treat cancer | ||
| 摘要 | The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | ||
| 申请公布号 | US9499629(B2) | 申请公布日期 | 2016.11.22 |
| 申请号 | US201113992622 | 申请日期 | 2011.12.09 |
| 申请人 | The Trustees of the University of Pennsylvania | 发明人 | June Carl H.;Levine Bruce L.;Porter David L.;Kalos Michael D.;Milone Michael C. |
| 分类号 | C12N5/071;C12N5/0783;C12N5/22;C07K16/28;A61K35/17;A61K39/00;A61K39/395;C12N15/85;C07K14/705;A61K48/00;C07K14/525;C07K14/725;C07K16/30;C12N7/00;A61K38/17;A61K45/06 | 主分类号 | C12N5/071 |
| 代理机构 | Saul Ewing LLP | 代理人 | Saul Ewing LLP ;Doyle Kathryn |
| 主权项 | 1. A method for stimulating a T cell-mediated immune response to a target cell population or tissue in a human, the method comprising administering to the human an effective amount of a cell genetically modified to express a CAR wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a costimulatory signaling region comprising 4-1BB, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO: 24, wherein the CD19 antigen binding domain specifically recognizes CD19 in the target cell population or tissue, wherein the cell is from a human having cancer. | ||
| 地址 | Philadelphia PA US | ||